Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial)

Sponsor
Insel Gruppe AG, University Hospital Bern
Study ID
NCT07478536
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
MALE
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Stockholm3 — DIAGNOSTIC_TEST
    Predictive value of Stockholm3 test in a prostate cancer cohort on Active Surveillance (AS) for upgrading on re-biopsy

Study Details

The CHAS3 trial studies whether the Stockholm3 blood test can reliably detect if prostate cancer becomes more aggressive in men who are being carefully monitored instead of treated right away (active surveillance). The goal is to see if this test can help doctors safely follow patients with fewer invasive procedures, such as repeated biopsies.

Key Dates

First listed
Mar 17, 2026
Start date
Jul 1, 2026
Status verified
Mar 2026
Primary completion
Mar 31, 2028
Completion
Aug 31, 2028

Study Design

Enrollment
350 participants (estimated)

Arms

  • Arm: Stockolm3 Blood test in prostate cancer patient under active surviellance
    Diagnostic procedure

Primary Outcome Measure

Diagnostic accuracy of the Stockholm3 test for detection of histological upgrading to ISUP Grade Group ≥2 at follow-up prostate biopsy [ Time Frame: At time of follow-up biopsy (baseline visit; Day 0 of study procedures) ]

Central Contacts

Find similar trials

Nationwide
Prostate cancer trialsOncology trialsProstate oncology trialsMen's health trialsUrology trials

Related Studies